Phase 3 N=525 Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
Gastric Cancer
Primary: Overall Survival — 82; 62 participants — p=0.0262
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=47 Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel
Acute Pain · Breast Carcinoma · Peripheral Neuropathy
Primary: Area Under the Curve (AUC) Per Assessment (aAUCpa) of Average Pain (Item 3 on the Daily Post-Paclitaxel Questionnaire) — 96.0; 84.3 scores on a scale — p=0.0186
N/A N=72 Clinical Trial of Factor XIII (FXIII) Concentrate
Hemophilia · Factor XIII Deficiency
Primary: Response to Treatment of Bleeding Events Requiring Additional Factor XIII Infusions — 30; 1; 0; 3 Number of bleeds
Phase 4 N=21 Wound Management for Sacral Pressure Ulcers With Necrotic Tissue
Pressure Ulcers
Primary: Percentage of Wounds Healed — 63.1; 6.1 percentage of wounds
N/A N=144 Balloon Catheter for Cervical Ripening
Cervical Dilation
Primary: Duration — 16.2; 16.9 hours — p=0.814
N/A N=278 Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients
Diabetes Mellitus, Type 2
Primary: Change in A1C From Baseline to the Completion of 24 Weeks of Basal and Bolus Insulin Therapy — -1.69; -1.60 A1C % — p=<0.0001
N/A N=509 Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention
Acute Coronary Syndrome · Cardiovascular Diseases
Primary: The Number (Percentage) of Participants Receiving Prasugrel/Ticagrelor — 174; 201; 75; 54 Participants — p=0.03
Phase 4 N=50 Paracervical Block Versus No Paracervical Block During IUD Insertion
Analgesia · IUD Insertion
Primary: Pain Score as Assessed by a Visual Analogue Scale (VAS) — 2.4; 2.1 units on a scale — p=0.59
Phase 4 N=20 A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients
Kidney Transplantation
Primary: Difference in Tacrolimus Exposure (AUC-0-24)) in Obese Patients Who Received an Initial TAC -ER Dose of 0.15 mg/kg Using aBW Versus IBW — 115.2; 90.0; 268.3; 269.3…
Phase 3 N=30 Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
Autism Spectrum Disorders
Primary: Mean 10-Week Change in Pediatric Anxiety Rating Scale 5-Item Total Score, Double-blind Phase — -4.9; -3.2 score on a scale
Phase 3 N=102 A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia
Alloimmune Thrombocytopenia · Fetal Alloimmune Thrombocytopenia
Primary: Number of Newborns With a Birth Platelet Count > 50,000/uL — 48; 47 number of newborns with >50,000 pets
N/A N=20 Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms
Dry Eye Syndrome
Primary: Change in Schirmer's Scores — -.30; -1.06 score on a scale
N/A N=258 HEMOBLAST Pivotal Clinical Investigation
Hemostasis
Primary: Proportion of Subjects Achieving Hemostasis — 148; 61 Participants — p=<0.0001
Phase 1 N=52 Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)
Diabetes Mellitus, Type 2 · Adult
Primary: Cumulative Urinary Glucose Excretion Over 0 to 24 Hours — 69.45; 70.43; 78.29; 80.54 Grams
N/A N=18 Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
Melasma
Primary: Change From Baseline in Melasma Severity Rating Scale Score to Week 12 — 2.1; 2.1; -0.3; -0.8 score on a scale — p=0.041